NICE says no to GW's Sativex; Germany best in Europe at dealing with mental illness;

@FiercePharma: Top-read special report in FP Tues: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer insists its probiotic marketing claims aren't full of hot air. Article | Follow @CarlyHFierce

> The Generic Pharmaceutical Association (GPhA) has challenged data cited by members of Congress who are launching an investigation into generic drug prices. Report

> In final draft guidance, the U.K.'s cost watchdog has recommended against the use of GW Pharmaceuticals' ($GWPH) cannabis-based Sativex. Report

> Teva ($TEVA) and the FDA are getting the process started on a tamper-resistant hydrocodone painkiller. Release

Medical Device News

@FierceMedDev: This week's issue of FierceDiagnostics is out! Sign up for free here. | Follow @FierceMedDev

@VarunSaxena2: Flowonix submits MRI-compatible implantable infusion pump for FDA approval. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Robot-assisted surgery often comes with more complications and higher costs, according to new study. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> At least $200M paid to docs by medical device industry. Item

> Becton plans on $9.1B bridge loan to finance deal with CareFusion. Story

> EU halts distribution of GI Dynamics obesity device. News

> Preview: Boston Scientific's Watchman goes before third FDA panel. More

Biotech News

@FierceBiotech: New special report: Top 7 life sciences public investors. Feature | Follow @FierceBiotech

@JohnCFierce: BIA did a report on bio-fundraising in the U.K. Hard to see where the promo ends and the analysis begins. Very Yank. More | Follow @JohnCFierce

@DamianFierce: | Follow @DamianFierce

@EmilyMFierce: Hmmm... Cancer tumours destroyed by berry found in Queensland rainforest. More from The Guardian | Follow @EmilyMFierce

> Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan. More

> Levicept emerges from Pfizer's R&D ashes with $20M and a new pain drug. Story

> Amgen declares a head-to-head PhIII win for Humira biosimilar. News

> Chimerix scores promising antiviral data from a controversy-fueled PhIII pilot. Article

Drug Delivery News

> Flat nanosheets roll drugs up and release them on command. Item

> With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. More

> Flowonix submits MRI-compatible implantable infusion pump for FDA approval. Story

> USPTO to review delivery patent in spat between Suboxone and BDSI's Bunavail. Report

> Alnylam says it wants to enter larger disease areas using partnership-driven approach. More

Diagnostics News

> MD Anderson pursues two projects targeting personalized prostate cancer testing. News

> Health Diagnostic Laboratory helps find promising predictive diabetes biomarkers. More

> Swedes, Harvard and more find success with DNA test for Afib risks. Report

> NanoString and a Harvard-affiliated hospital hope to quicken creation of new cancer tests. Story

> Quest, in transition, recruits Mayo Clinic exec to run major division. Article

Pharma Marketing News

> Analysts: Actavis-Allergan deal could create a marketing superpower. Item

> Pfizer's new #viagracommercial lights up Twitter during MLB playoffs--and not in a good way. More

> Merck hops onto HBCU network to step up its brand in the African-American community. Report

> Hand out prizes for adherence? West and HealthPrize team up to test the idea. Story

> Balking at marketing slapdown, Galderma declares itself pharma non grata. Article

And Finally... Of 30 European countries, Germany, closely followed by the U.K., is most able to respond to the needs of people who suffer from mental illness. More

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.